Indivior Pharmaceuticals Inc (Indivior) develops, manufactures, and sells buprenorphine-based prescription pharmaceuticals for the treatment of opioid dependence. The company operates through one reportable segment, the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and related disorders. The company’s product portfolio includes buprenorphine-based Suboxone (buprenorphine and naloxone) tablet, Suboxone (buprenorphine and naloxone) sublingual film, Sublocade (buprenorphine extended-release) injection and Subutex (buprenorphine) tablet for the treatment of opioid dependence. Indivior also offers Perseris (risperidone) extended-release injectable suspension for schizophrenia and Opvee (Nalmefene), a nasal spray for the treatment of opioid overdose reversal.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

The company's R&D activities focus on the development and discovery of treatment strategies for opioid use disorder (OUD). The company's R&D efforts include creating innovative medications and services to address the needs of patients with substance use disorder (SUD). This includes developing new medications designed to minimize diversion and misuse, increase compliance with treatment, support public health, improve patient outcomes, and expand access to treatment. Indivior supports the SUD treatment community, including the discovery of buprenorphine and the development of a portfolio of treatments for OUD. The company is also involved in opioid overdose reversal research and has contributed to the regulatory approval of OPVEE (nalmefene) nasal spray for emergency treatment of opioid overdose. Indivior's R&D activities are managed through several units: Global Chemistry, Manufacturing, and Controls (CMC), is responsible for formulation development, analytical development, chemical development, process development, and technology transfer. It operates facilities in Hull, the UK, and Fort Collins, Colorado, the US. Global Medicines Development unit supports clinical and nonclinical development, including clinical trials, medical and scientific writing, data and statistical sciences, clinical pharmacology, epidemiology, and safety compliance. The Global Regulatory Affairs unit focuses on regulatory strategy, compliance, operations, global labeling, and local regulatory affairs in various regions, including North America, Europe, the Middle East, and Australasia. The company owns or licenses several patents and patent rights in the US and other countries. The pipeline includes products such as INDV-2000, a selective orexin-1 receptor antagonist, and INDV-6001, a sustained-release LAI prodrug of buprenorphine. The company has secured global rights from Alar Pharmaceuticals to develop, manufacture, and commercialize INDV-6001 and a portfolio of buprenorphine-based LAI. In FY2025, the company spent US$97 million on its R&D activities, which as a percentage of revenue stood at 7.8%. As of December 2025, the company had 72 employees working in the R&D division.